Literature DB >> 18790987

Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.

C N Sternberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18790987     DOI： 10.1093/annonc/mdn473

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

1.  Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.

Authors:  A Dirican; H Atmaca; E Bozkurt; C Erten; B Karaca; R Uslu
Journal:  Clin Transl Oncol       Date:  2014-07-25       Impact factor: 3.405

2.  A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.

Authors:  Nai-Dong Xing; Sen-Tai Ding; Ryoichi Saito; Koji Nishizawa; Takashi Kobayashi; Takahiro Inoue; Shinya Oishi; Nobutaka Fujii; Jia-Jv Lv; Osamu Ogawa; Hiroyuki Nishiyama
Journal:  Asian J Androl       Date:  2011-02-07       Impact factor: 3.285

3.  A good molecular target for prostate cancer chemotherapy.

Authors:  Sidney R Grimes
Journal:  Asian J Androl       Date:  2011-02-14       Impact factor: 3.285

4.  A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.

Authors:  Hoai-Thu Thai; Christine Veyrat-Follet; Nicole Vivier; Catherine Dubruc; Gerard Sanderink; France Mentré; Emmanuelle Comets
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

Review 5.  Evolving role of bone biomarkers in castration-resistant prostate cancer.

Authors:  Janet E Brown; Sheryl Sim
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

6.  Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Authors:  Alym Abdulla; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

7.  Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing.

Authors:  Elsa Sousa; Inês Graça; Tiago Baptista; Filipa Q Vieira; Carlos Palmeira; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2013-04-17       Impact factor: 4.528

8.  An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy.

Authors:  Fayun Zhang; Liang Shan; Yuanyi Liu; David Neville; Jung-Hee Woo; Yue Chen; Alexandru Korotcov; Stephen Lin; Sophia Huang; Rajagopalan Sridhar; Wei Liang; Paul C Wang
Journal:  Adv Healthc Mater       Date:  2012-11-22       Impact factor: 9.933

9.  A changing landscape in castration-resistant prostate cancer treatment.

Authors:  A Felici; M S Pino; Paolo Carlini
Journal:  Front Endocrinol (Lausanne)       Date:  2012-07-18       Impact factor: 5.555

10.  PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report.

Authors:  Joan Manel Gasent Blesa; Miguel Peris Godoy; María Fonfría Esparcia; Sara Blasco Mollá; Balbino Mancheño Magán; José Miguel Sempere Ortells; José Luis Sánchez
Journal:  Case Rep Oncol       Date:  2012-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.